Original Article

Antioxidant and Anti-aging Activities of Silybum Marianum Protein Hydrolysate in Mice Treated with D-galactose

ZHU Shu Yun¹,²,³, JIANG Ning³,⁴, TU Jie⁴, YANG Jing¹, and ZHOU Yue¹

1. School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, Jiangsu, China; 2. Jiangsu Hengshun Group Co. Ltd., Zhenjiang 212000, Jiangsu, China; 3. Institute of Vegetables, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, Jiangsu, China; 4. College of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212018, Jiangsu, China

Abstract

Objective In the present study, we investigated the antioxidant and anti-aging effects of Silybum marianum protein hydrolysate (SMPH) in D-galactose-treated mice.

Methods D-galactose (500 mg/kg body weight) was intraperitoneally injected daily for 7 weeks to accelerate aging, and SMPH (400, 800, 1,200 mg/kg body weight, respectively) was simultaneously administered orally. The antioxidant and anti-aging effects of SMPH in the liver and brain were measured by biochemical assays. Transmission electron microscopy (TEM) was performed to study the ultrastructure of liver mitochondria.

Results SMPH decreased triglyceride and cholesterol levels in the D-galactose-treated mice. It significantly elevated the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), and total antioxidant capacity (T-AOC), which were suppressed by D-galactose. Monoamine oxidase (MAO) and malondialdehyde (MDA) levels as well as the concentrations of caspase-3 and 8-OHdG in the liver and brain were significantly reduced by SMPH. Moreover, it increased Bcl-2 levels in the liver and brain. Furthermore, SMPH significantly attenuated D-galactose-induced liver mitochondrial dysfunction by improving the activities of Na⁺-K⁺-ATPase and Ca²⁺-Mg²⁺-ATPase as well as mitochondrial membrane potential (ΔΨm) and fluidity. TEM showed that the degree of liver mitochondrial damage was significantly decreased by SMPH.

Conclusion The results indicated that SMPH protects against D-galactose-induced accelerated aging in mice through its antioxidant and anti-aging activities.

Key words: Silybum marianum protein hydrolysate; Antioxidant; Anti-aging; D-galactose

INTRODUCTION

Aging is a progressive, physiological impairment involving various organs and tissues. Increase in oxidative stress drives the pathophysiology of various diseases, including aging. An excessive increase in reactive oxygen species (ROS) levels damages cellular lipids, proteins, and DNA, inhibiting their normal functions and resulting in cell aging and death[1-3]. Moreover,

*This study was supported by University natural science foundation of Jiangsu Province (16KJB550001); Postdoctoral research funding project of Jiangsu Province (1601058A); and key research and development plan of Zhenjiang city (NY2016020).

ZHOU Shu Yun and JIANG Ning contributed equally to this work and should be considered co-first authors.

¹Correspondence should be addressed to ZHU Shu Yun, PhD, Tel: 86-511-88780201, E-mail: shyzhu@ujs.edu.cn

Biographical notes of the first authors: ZHU Shu Yun, female, born in 1975, Associate Professor, PhD, majoring in food nutrition; JIANG Ning, male, born in 1975, Associate Professor, Master, majoring in biotechnology.
oxidative stress triggers the pathogenesis of age-associated or neurodegenerative diseases\textsuperscript{[4-5]}. D-galactose is a reducing sugar that accelerates aging by decreasing the activities of antioxidant enzymes and impairing the functions of macromolecules and cells, especially neurons\textsuperscript{[6]}. Accelerated aging using D-galactose is a long-standing preclinical model\textsuperscript{[7]}. It induces oxidative stress and tissue injury, leading to cellular apoptosis, cognitive impairment, mitochondrial dysfunction, and a decline in the function of antioxidant defense systems\textsuperscript{[8-10]}. Mitochondrial dysfunction extensively leads to aging and age-associated degeneration\textsuperscript{[11]}

Dietary antioxidants and mitochondrial nutrients delay aging and ameliorate age-associated diseases\textsuperscript{[12-13]}. Certain bioactive peptides combat oxidative stress and memory deficits\textsuperscript{[14-15]}. Accordingly, hydrolysis of proteins is a feasible approach to produce biologically active peptides\textsuperscript{[16]}. Antioxidant peptides with potent free radical-scavenging activities prevent oxidative tissue damage and delay aging.

\textit{Silybum marianum} L. Gaernt is an annual or biennial Mediterranean plant that has been used to treat liver diseases for over 2000 years. Flavonolignans, collectively known as silymarin, are abundantly found in this plant. It is mainly present in the shell and kernel of the seed, and contains protein and oil\textsuperscript{[17-19]}. Protein by-products of silymarin biosynthesis in seed kernels are rich in essential amino acids that are highly valuable\textsuperscript{[20-21]}. Furthermore, \textit{S. marianum} protein hydrolysate (SMPH) has \textit{in vitro} antioxidant effects\textsuperscript{[22]}. Oligopeptides in \textit{S. marianum} are reported to inhibit liver mitochondrial injury induced by hydroxyl ions in mice\textsuperscript{[23]}. Natural antioxidants are preferred because they are considered safer than synthetic antioxidants. Therefore, development of protein hydrolysates as natural antioxidants or neuroprotective agents has gained importance\textsuperscript{[14-16]}. We previously demonstrated antioxidant activities of SMPH \textit{in vitro}. In this study, to further establish its antioxidant and anti-aging potential \textit{in vivo}, we used a model of accelerated aging by chronically injecting ICR mice with D-galactose.

\textbf{MATERIALS AND METHODS}

\textbf{Reagents and Drugs}

D-galactose was purchased from Amresco Inc. (USA). Rhodamine 123 was purchased from Beyotime Institute of Biotechnology (Haimen, China). Total antioxidant capacity (T-AOC), and levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), monoamine oxidase (MAO), malondialdehyde (MDA), Na\textsuperscript{+}-K\textsuperscript{+}-ATPase, and Ca\textsuperscript{2+}-Mg\textsuperscript{2+}-ATPase were determined by commercial kits purchased from Nanjing Jiancheng Institute of Biological Engineering (Nanjing, China). ELISA kits for quantifying 8-OHdG, caspase-3, and Bcl-2 were purchased from Shanghai Jianglai Bioscience Co. Ltd. (Shanghai, China). 1,6-diphenyhexa-1,3,5-triene (DPH) was purchased from Sigma (USA).

\textbf{Preparation of SMPH}

Seeds of \textit{S. marianum} were obtained from Jiangsu Zhongxing Pharm. Co. Ltd., and identified by Prof. Jun Chen (School of Pharmacy, Jiangsu University). Proteins from the seeds were isolated in our laboratory by alkali extraction and acid precipitation\textsuperscript{[24]}. Briefly, \textit{S. marianum} seeds were powdered, defatted with hexane, and dispersed in 16 parts of deionized alkaline water (pH 11) at 50 °C for 1 h. The slurry was centrifuged (1,500 xg, 30 min), and the supernatant was adjusted to pH 5.5 and centrifuged again. Proteins in the supernatant were re-dispersed in deionized water (pH 7), and freeze-dried. This freeze-dried protein fraction (protein content: 84.53% ± 0.52%) was hydrolyzed by Neutrase\textsuperscript{®} at a substrate:enzyme ratio of 60:1 (w/w) under optimal conditions (pH 7, 55 °C for 2 h). The hydrolysis was thermally stopped using a boiling water bath for 10 min. After cooling to room temperature, the SMPH obtained was centrifuged (6,500 xg, 4 °C, 15 min) and freeze-dried. The composition of SMPH by molecular weight was as follows: < 1 kD, 64.74%; 1-3 kD, 9.52%; 3-10 kD, 13.46%; ≥ 10 kD, 12.28%.

\textbf{Animals and Treatment}

ICR mice (female, 3-month-old) were housed in an animal house at the Laboratory Animal Research Center of Jiangsu University, Zhenjiang, China. The license number of the mice was SCXK (SU) 2013-0011. After acclimation for a week, the mice were randomized into 5 groups (n = 10/group). Mice in group 1 were injected saline (vehicle control group), and the other groups of mice received daily intraperitoneal injection of D-galactose (positive control group) at a dose of 500 mg/kg for 7 weeks. Simultaneously, mice in groups 3, 4, and 5 were orally administered SMPH at doses of 400, 800, and
1,200 mg/kg, respectively, daily for 7 weeks; mice in groups 1 and 2 were orally administered the same volume of distilled water. During the entire experimental period (including acclimation), the mice were allowed unrestricted access to standard rodent diet and water. All procedures were approved by the Laboratory Animal Management Committee of Jiangsu University and adhered to guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. After 7 weeks, the mice were humanely euthanized, and the brains and livers were promptly removed and stored at -80 °C until analysis. Blood samples were collected and centrifuged (1,000 ×g, 15 min, 4 °C) to separate the sera. Brain and liver homogenates (10%) were centrifuged (1,500 ×g, 15 min, 4 °C) and the supernatants were used for biochemical analysis.

**Isolation of Liver Mitochondria**

Liver mitochondrial fraction was prepared according to the method described by Tang et al. with some modifications. Briefly, the liver was homogenized with ice-cold isolation buffer (0.25 mol/L sucrose, 5 mmol/L Tris-HCl, and 1 mmol/L EDTA, pH 7.4) and centrifuged (1,000 ×g, 10 min). The supernatant was subjected to high-speed centrifugation (8,000 ×g, 15 min, 4 °C) to obtain the mitochondrial pellet. After washing and centrifuging (8,000 ×g) twice, the pellet was re-suspended in assay-specific buffers.

**Serum Biochemical Indices**

The sera were assayed for glucose, cholesterol, triglycerides, high-density lipoprotein cholesterol (HDLC), and low-density lipoprotein cholesterol (LDLC) levels, using an Olympus AU2700 clinical chemistry analyzer (Olympus Inc., Japan).

**Biochemical Analyses**

Commercially available kits were used to determine the levels of protein, SOD, GSH-Px, T-AOC, MDA, MAO, Na⁺-K⁺-ATPase, and Ca²⁺-Mg²⁺-ATPase. 8-OHdG, caspase-3, and Bcl-2 levels were determined using ELISA kits. All procedures were carried out according to the manufacturers’ instructions.

**Mitochondrial Membrane Potential (ΔΨm) Assay**

The ΔΨm was measured according to the method described by Zhu et al. Briefly, the mitochondrial suspension was incubated with a rhodamine 123 fluorescence probe for 20 min at 37 °C. After sedimentation, the mitochondria were washed twice and resuspended in phosphate-buffered saline. Fluorescence intensity was recorded using a Cary Eclipse spectrophotofluorometer (America Varian Technology China Ltd.) at ex/em: 505/534 nm.

**Mitochondrial Membrane Fluidity**

Measurement of mitochondrial membrane fluidity was carried out using a DPH probe in a Cary Eclipse spectrophotofluorometer, as described by Zhou et al. The mitochondria were incubated with DPH (10⁻⁶ mol/L) at 30 °C for 30 min in the dark. Fluorescence intensity was measured at ex/em: 361/431 nm at 25 °C. Fluorescence polarization (P) was calculated as

\[
P = \frac{I_{vv} - G I_{vh}}{I_{vh} + G I_{hv}},
\]

where \(I_{vv}, I_{vh}, I_{hv}, I_{hh}\) are the intensities of light at 431 nm, 431 nm, 505 nm, and 505 nm, respectively, and \(G\) is the grating correction factor, equal to \(I_{hh}/I_{hv}\). The polarization value inversely correlates with the membrane fluidity.

**TEM Analysis**

The liver was isolated, washed with physiological saline, and cut into small blocks (1 mm³) that were immediately fixed in a solution containing 2.5% formaldehyde-glutaraldehyde and post-fixed in 1% osmium tetroxide solution. Further, they were serially dehydrated in ethanol. After replacing ethanol with propylene oxide, the blocks were embedded in an epoxy resin, and ultrathin sections were obtained. The sections were double-stained with uranyl acetate and lead citrate, and observed under a Tecnai12 TEM.

**Statistical Analysis**

Statistical analysis was performed using SPSS, version 17.0. The values were analyzed by one-way analysis of variance (ANOVA), followed by Duncan’s multiple comparisons test. All the results are expressed as mean ± SD, and differences were considered statistically significant at \(P < 0.05\).

**RESULTS**

**Serum Biochemistry**

No significant \((P > 0.05)\) differences in the levels...
of glucose, HDLC, and LDLC were observed among the five groups (Table 1). However, the levels of cholesterol and triglycerides were significantly ($P < 0.05$) higher in positive control mice than in vehicle control mice. SMPH significantly decreased the level of triglycerides at 400 mg/kg. However, the level of cholesterol in positive control mice was significantly decreased only at a dose of 800 mg/kg of SMPH. Since pharmacological effects of a complex mixture are dependent on the concentration of its individual components, we observed that a dose of 800 mg/kg was effective in reducing cholesterol levels.

**Activities of GSH-Px and SOD, T-AOC, and MDA Level in the Liver**

To determine whether SMPH attenuates oxidative damage in the livers of D-galactose-treated mice, we measured the activities of GSH-Px and SOD along with T-AOC and MDA level in the liver (Table 2). SOD and GSH-Px activities as well as T-AOC were significantly lower in positive-control mice than in vehicle control mice. Moreover, D-galactose treatment reduced the level of MDA. However, supplementation with SMPH effectively countered the effect of D-galactose.

**Table 1. Levels of Glucose, Cholesterol, Triglycerides, High-density Lipoprotein Cholesterol (HDLC), and Low-density Lipoprotein Cholesterol (LDLC) in the Serum**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Glucose (mmol/L)</th>
<th>Cholesterol (mmol/L)</th>
<th>Triglycerides (mmol/L)</th>
<th>HDLC (mmol/L)</th>
<th>LDLC (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control</td>
<td>4.32 ± 0.79a</td>
<td>2.06 ± 0.22a</td>
<td>2.28 ± 0.71a</td>
<td>1.95 ± 0.22a</td>
<td>0.24 ± 0.04a</td>
</tr>
<tr>
<td>Positive control</td>
<td>4.87 ± 0.71a</td>
<td>2.56 ± 0.58a</td>
<td>2.99 ± 1.08b</td>
<td>2.11 ± 0.43a</td>
<td>0.21 ± 0.06a</td>
</tr>
<tr>
<td>SMPH (400 mg/kg)</td>
<td>4.25 ± 0.87a</td>
<td>2.23 ± 0.22ab</td>
<td>2.29 ± 0.44a</td>
<td>1.96 ± 0.24a</td>
<td>0.27 ± 0.21a</td>
</tr>
<tr>
<td>SMPH (800 mg/kg)</td>
<td>4.23 ± 0.36a</td>
<td>2.11 ± 0.26a</td>
<td>1.62 ± 0.31a</td>
<td>1.94 ± 0.19a</td>
<td>0.19 ± 0.05a</td>
</tr>
<tr>
<td>SMPH (1,200 mg/kg)</td>
<td>4.70 ± 0.78a</td>
<td>2.31 ± 0.30a</td>
<td>2.12 ± 0.50a</td>
<td>2.15 ± 0.35a</td>
<td>0.22 ± 0.05a</td>
</tr>
</tbody>
</table>

*Note.* Data are expressed as mean ± SD ($n = 10$); different letters indicate a significant difference ($P < 0.05$); Positive Control: D-galactose-treated mice; SMPH: D-galactose-treated mice receiving SMPH.

**Table 2. Activities of Glutathione Peroxidase (GSH-Px) and Superoxide Dismutase (SOD), Total Antioxidant Capacity (T-AOC), and Malondialdehyde (MDA) Level in the Liver**

<table>
<thead>
<tr>
<th>Groups</th>
<th>SOD (U/mg protein)</th>
<th>GSH-Px (U/mg protein)</th>
<th>T-AOC (U/mg protein)</th>
<th>MDA (nmol/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control</td>
<td>33.27 ± 4.09&lt;sup&gt;a&lt;/sup&gt;</td>
<td>415.91 ± 27.60&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.02 ± 0.15&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.14 ± 0.53&lt;sup&gt;abc&lt;/sup&gt;</td>
</tr>
<tr>
<td>Positive control</td>
<td>24.37 ± 6.05&lt;sup&gt;b&lt;/sup&gt;</td>
<td>273.66 ± 43.57&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.62 ± 0.13&lt;sup&gt;b&lt;/sup&gt;</td>
<td>11.52 ± 0.29&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>SMPH (400 mg/kg)</td>
<td>32.37 ± 5.18&lt;sup&gt;c&lt;/sup&gt;</td>
<td>388.96 ± 22.89&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.64 ± 0.06&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6.11 ± 0.47&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>SMPH (800 mg/kg)</td>
<td>36.11 ± 5.45&lt;sup&gt;d&lt;/sup&gt;</td>
<td>412.37 ± 33.01&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.89 ± 0.21&lt;sup&gt;c&lt;/sup&gt;</td>
<td>8.11 ± 0.89&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>SMPH (1,200 mg/kg)</td>
<td>32.17 ± 3.88&lt;sup&gt;e&lt;/sup&gt;</td>
<td>359.88 ± 28.52&lt;sup&gt;e&lt;/sup&gt;</td>
<td>0.81 ± 0.07&lt;sup&gt;e&lt;/sup&gt;</td>
<td>7.30 ± 1.06&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*Note.* Data are expressed as mean ± SD ($n = 10$); different letters indicate a significant difference ($P < 0.05$); Positive Control: D-galactose-treated mice; SMPH: D-galactose-treated mice receiving SMPH.

**Activities of GSH-Px and SOD, T-AOC, and the Levels of MAO and MDA in the Brain**

The activities of GSH-Px and SOD as well as T-AOC were significantly lower, and MAO and MDA levels were significantly higher in the brains of positive control mice than in the brains of vehicle control mice (Table 3). However, SMPH treatment significantly increased the activities of GSH-Px and SOD, and decreased both MAO and MDA levels in the brain. No significant differences in the levels of T-AOC were observed between mice treated with SMPH and positive control mice. Further, the levels of GSH-Px, SOD, MAO, and MDA in the brains of vehicle control mice did not significantly differ from those in the brains of SMPH-treated mice.

**Concentrations of 8-OHdG, Bcl-2, and Caspase-3 in the Liver and Brain**

The level of Bcl-2 was significantly lower, while the levels of 8-OHdG and caspase-3 were significantly higher in positive-control mice than in vehicle control mice (Figure 1). By contrast, SMPH-treated mice had significantly higher levels of Bcl-2 and lower levels of 8-OHdG and caspase-3 in...
the brains and livers than positive control mice. No
significant differences in the levels of Bcl-2 and
caspase-3 were observed between vehicle control
and SMMPH-treated mice.

Liver Mitochondrial Membrane Fluidity and ΔΨm

The effect of SMMPH on membrane fluidity was
demonstrated by reduced η and P values in
SMMPH-treated mice relative to those in positive
control mice (Table 4). η and P values in the liver
mitochondrial membrane were significantly higher in
positive control mice than in vehicle control mice.
However, SMMPH significantly decreased these values.
The liver ΔΨm was significantly lower in positive
control mice than in vehicle control mice. Treatment
with SMMPH significantly increased the ΔΨm.

Activities of Na⁺-K⁺-ATPase and Ca²⁺-Mg²⁺-ATPase in
Liver Mitochondria

The effect of SMMPH on the activities of
Na⁺-K⁺-ATPase and Ca²⁺-Mg²⁺-ATPase are presented in
Table 5. The activities of Na⁺-K⁺-ATPase and Ca²⁺-Mg²⁺

---

**Table 3.** Activities of Glutathione Peroxidase (GSH-Px) and Superoxide Dismutase (SOD), Total Antioxidant
Capacity (T-AOC), and Levels of Monoamine Oxidase (MAO) and Malondialdehyde (MDA) in the Brain

<table>
<thead>
<tr>
<th>Groups</th>
<th>SOD (U/mg protein)</th>
<th>GSH-Px (U/mg protein)</th>
<th>T-AOC (U/mg protein)</th>
<th>MAO (U/mg protein)</th>
<th>MDA (nmol/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control</td>
<td>65.53 ± 9.16a</td>
<td>16.17 ± 4.11a</td>
<td>0.40 ± 0.08a</td>
<td>1.20 ± 0.27a</td>
<td>3.52 ± 0.25a</td>
</tr>
<tr>
<td>Positive control</td>
<td>41.06 ± 2.64b</td>
<td>7.33 ± 3.14b</td>
<td>0.23 ± 0.07b</td>
<td>1.94 ± 0.31b</td>
<td>5.06 ± 0.64b</td>
</tr>
<tr>
<td>SMMPH (400 mg/kg)</td>
<td>62.25 ± 9.83a</td>
<td>17.29 ± 3.14a</td>
<td>0.25 ± 0.06a</td>
<td>1.49 ± 0.34a</td>
<td>3.92 ± 0.20a</td>
</tr>
<tr>
<td>SMMPH (800 mg/kg)</td>
<td>62.69 ± 3.45a</td>
<td>19.61 ± 3.52a</td>
<td>0.24 ± 0.05a</td>
<td>1.16 ± 0.24a</td>
<td>3.43 ± 0.47a</td>
</tr>
<tr>
<td>SMMPH (1,200 mg/kg)</td>
<td>58.54 ± 7.37a</td>
<td>18.56 ± 2.22a</td>
<td>0.24 ± 0.04a</td>
<td>1.28 ± 0.12a</td>
<td>3.98 ± 0.21a</td>
</tr>
</tbody>
</table>

**Note.** Data are expressed as mean ± SD (n = 10); different letters indicate a significant difference (P < 0.05); Positive Control: D-galactose-treated mice; SMMPH: D-galactose-treated mice receiving SMMPH.

**Table 4.** Liver Mitochondrial Membrane Potential (ΔΨm) and Fluidity

<table>
<thead>
<tr>
<th>Groups</th>
<th>ΔΨm</th>
<th>Fluorescence polarization (P)</th>
<th>Microviscosity (η)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control</td>
<td>44.46 ± 0.48a</td>
<td>0.16 ± 0.02a</td>
<td>1.05 ± 0.15a</td>
</tr>
<tr>
<td>Positive control</td>
<td>24.94 ± 1.54b</td>
<td>0.32 ± 0.02b</td>
<td>4.49 ± 0.69b</td>
</tr>
<tr>
<td>SMMPH (400 mg/kg)</td>
<td>38.33 ± 1.61c</td>
<td>0.27 ± 0.03c</td>
<td>2.82 ± 0.62c</td>
</tr>
<tr>
<td>SMMPH (800 mg/kg)</td>
<td>39.61 ± 0.73d</td>
<td>0.22 ± 0.02d</td>
<td>1.89 ± 0.26d</td>
</tr>
<tr>
<td>SMMPH (1,200 mg/kg)</td>
<td>39.50 ± 0.89e</td>
<td>0.21 ± 0.02e</td>
<td>1.76 ± 0.22e</td>
</tr>
</tbody>
</table>

**Note.** Data are expressed as mean ± SD (n = 10); different letters indicate a significant difference (P < 0.05); Positive Control: D-galactose-treated mice; SMMPH: D-galactose-treated mice receiving SMMPH.
-ATPase were significantly lower in positive control mice than in vehicle control mice. In contrast, their activities were significantly increased in SMPH-treated mice compared with those in positive control mice.

**Ultrastructural Changes in Liver Mitochondria**

Ultrastructural changes in liver mitochondria were observed by TEM (Figure 2). The results showed that D-galactose treatment led to liver mitochondrial oxidative damage. Mitochondria in positive control mice exhibited swelling and vacuolization or disruption of mitochondrial cristae (Figure 2B). Treatment with SMPH ameliorated these morphological changes, and mitochondria in SMPH-treated mice were less swollen with intact membranes.

**DISCUSSION**

Aging is characterized by an accelerated decline in physiological performance and physical activity. D-Galactose-induced aging is used as an experimental animal model to study aging and develop anti-aging strategies. D-galactose increases the level of free radicals in animals. The free radical theory of aging suggests that an increased level of free radicals leads to age-related degenerative diseases.

These free radicals cause cell damage and death. SOD, GSH-Px, and CAT are the most important antioxidant enzymes that inhibit free radical formation and are used as biomarkers of excessive ROS production. They act as the primary defense system against ROS during oxidative stress. Under normal physiological conditions, SOD, CAT, and GSH-Px efficiently counteract oxidative damage induced by free radicals. However, they are overwhelmed under excessive oxidative stress conditions. In the present study, the activities of SOD and GSH-Px were found to be significantly lower in the liver and brain of D-galactose-treated mice than in vehicle control mice; however, SMPH significantly increased their activities. Determination of T-AOC enables quantification of the non-enzymatic endogenous antioxidant potential. We observed that SMPH treatment increased the T-AOC in the liver, indicating that the function of the non-enzymatic antioxidant

**Table 5. Activities of Na⁺-K⁺-ATPase and Ca²⁺-Mg²⁺-ATPase in Liver Mitochondria**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Na⁺-K⁺-ATPase (U/mg protein)</th>
<th>Ca²⁺-Mg²⁺-ATPase (U/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control</td>
<td>6.92 ± 0.55^a</td>
<td>5.35 ± 0.32^a</td>
</tr>
<tr>
<td>Positive control</td>
<td>3.06 ± 0.14^b</td>
<td>2.62 ± 0.39^b</td>
</tr>
<tr>
<td>SMPH (400 mg/kg)</td>
<td>4.03 ± 0.26^c</td>
<td>3.66 ± 0.87^d</td>
</tr>
<tr>
<td>SMPH (800 mg/kg)</td>
<td>4.59 ± 0.31^cd</td>
<td>4.23 ± 0.38^e</td>
</tr>
<tr>
<td>SMPH (1,200 mg/kg)</td>
<td>4.62 ± 0.38^d</td>
<td>3.79 ± 0.29^e</td>
</tr>
</tbody>
</table>

**Note.** Data are expressed as mean ± SD (n = 10); different letters indicate a significant difference (P < 0.05); Positive Control: D-galactose-treated mice; SMPH: D-galactose-treated mice receiving SMPH.

**Figure 2.** Ultrastructure of liver mitochondria was examined by TEM (magnification 3,900). (A) vehicle control mice; (B) D-galactose-treated mice; (C) D-galactose-treated mice receiving SMPH (800 mg/kg). Bar = 1 μm.
The anti-aging effect of *Silybum marianum* protein hydrolysate

629
defense system in D-galactose-treated mice was enhanced. We previously demonstrated the *in vitro* antioxidant activities of SMPH. In the present study, we showed that SMPH exhibits free radical-scavenging antioxidant capacity in D-galactose-treated mice.

An increase in ROS levels induces lipid peroxidation, which is also associated with aging. Therefore, inhibition of lipid peroxidation prevents free-radical-mediated diseases[37]. Peroxidation of polyunsaturated fatty acids in biological membranes leads to the formation of MDA. Therefore, it is used as an indicator of oxidative stress damage. The levels of MDA were significantly higher in the liver and brain of positive control mice than in vehicle control mice (Tables 2 and 3). Moreover, treatment with D-galactose induced lipid peroxidation in mice by increasing the production of ROS. Similar findings have been reported in tissues of D-galactose-treated mice[38]. Treatment with SMPH significantly reduced the levels of MDA in both the liver and brain of mice. These results indicated that SMPH exerts antioxidant effects by preventing ROS-induced lipid peroxidation in D-galactose-treated mice.

MAO catalyzes the degradation of neuroactive and vasoactive amines, and its activation is associated with age-related disturbances, imbalance in homeostasis, and generation of free radicals in nerve tissues[39]. In our study, the activity of brain MAO was significantly higher in positive control mice than in vehicle control mice. However, the administration of SMPH significantly prevented this increase and attenuated monoamine metabolism. As a biomarker of oxidative DNA damage, significantly higher levels of 8-OHdG were observed in the liver and brain of positive control mice than in vehicle control mice (Figure 1A). These results suggested that D-galactose induces oxidative DNA damage in mice. Treatment with SMPH significantly reduced the levels of 8-OHdG in both the liver and brain of mice, indicating that the administration of SMPH effectively inhibits oxidative DNA damage in D-galactose-treated mice.

Apoptosis is a biological process that plays a crucial role in the normal tissue development and homeostasis. In this study, D-galactose significantly increased apoptosis in the liver and brain, whereas SMPH treatment significantly reduced it (Figure 1B and 1C).

Bcl-2 is a proto-oncogene that regulates the mitochondrial apoptotic pathway[40]. In our study, we found that D-galactose decreased the levels of Bcl-2 in the liver and brain. However, SMPH treatment prevented the decline in Bcl-2 levels (Figure 1B), owing to its antioxidant property. Caspase-3 is another regulator of apoptosis and is activated by ROS, leading to neuronal dysfunction[41]. In the present study, we found that SMPH reduced caspase-3 activity in the liver and brain of D-galactose-treated mice (Figure 1C). These results suggested that SMPH regulates the expression of mitochondrial apoptosis-related proteins by mitigating oxidative stress.

Oxidative mitochondrial damage accelerates aging[42]. It is considered a hallmark of cellular aging and is the major source of ROS[43]. ROS-oxidized mitochondrial membrane lipids exhibit reduced fluidity and increased permeability[44-45]. In this study, we found that chronic treatment with D-galactose induces mitochondrial dysfunction in the liver of mice, whereas treatment with SMPH effectively ameliorated D-galactose-induced mitochondrial dysfunction (Tables 4-5, and Figure 2).

The mitochondrial membrane fluidity and potential reflect the biophysical and biochemical health of the mitochondrial membrane[46]. In this study, a significant reduction in the membrane potential and fluidity was observed in liver mitochondria when mice were treated with D-galactose. However, SMPH significantly prevented this reduction owing to its antioxidant potential, thereby preventing mitochondrial membrane damage. Mitochondrial oxidative phosphorylation is the primary source of energy for metabolism. About 40% of the total ATP is consumed by Na⁺-ATPase and Ca²⁺-Mg²⁺-ATPase, which maintain the plasma membrane potential and intracellular Ca²⁺ stores[47]. In the present study, the activities of Na⁺-ATPase and Ca²⁺-Mg²⁺-ATPase were lower in the liver mitochondria of positive control mice than in vehicle control mice. Treatment with SMPH significantly increased their activities by preventing free radical-induced membrane damage. Our results also revealed abnormal liver mitochondria in D-galactose-treated mice; the degree of liver mitochondrial damage was significantly decreased with administration of SMPH. We previously showed that oligopeptides of *S. marianum* inhibit liver mitochondrial injury induced by hydroxyl ions in mice. The present study showed that SMPH attenuated D-galactose-induced liver mitochondrial dysfunction. Since digestion of proteins produces free amino acids and oligopeptides that are absorbed into the blood, the protective effects of.
SMPH could be due to either the free amino acids or its hydrolysis product after systemic absorption to counteract D-galactose-mediated damage.

CONCLUSION

In conclusion, the results of this study indicated that SMPH protects against D-galactose-induced aging in mice. It increases the activities of antioxidant enzymes, attenuates lipid peroxidation, modulates the production of apoptosis-related factors, and prevents mitochondrial damage induced by D-galactose. Based on these findings, SMPH may be developed into a novel functional food material that prevents oxidative tissue damage and age-related diseases.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

ZHOU Shu Yun designed this study, collected test data, and wrote the manuscript; JIANG Ning and TU Jie participated in the writing and revising of the manuscript; YANG Jing performed the statistical analyses; ZHOU Yue assisted in the animal experiments and collected the test data. All authors have read and approved the final manuscript.

Received: June 22, 2017; Accepted: September 1, 2017

REFERENCES

27. Zhou XM, Cao YL, Dou DQ. Protective effect of ginsenoside-Re against cerebral ischemia/reperfusion damage in rats. Biol
The anti-aging effect of *Silybum marianum* protein hydrolysate

Pharm Bull, 2006; 29, 2502-5.


